Program
sunakiment
Also written as “AZD8630”, “AZD8630 (test formulation) via test inhaler” and “AZD8630 (reference formulation) via Monodose inhaler”.
Its studies are mostly in Asthma, led by AstraZeneca.
Drug pageSunakiment: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 50 open or running | phase 2since Jul 15, 2024 | Oct 28, 2021 | none ahead |
- Named in AstraZeneca’s own pipeline as
sunakiment (AZD8630)
, phase 2, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 28, 2021First study: phase 1 study in AsthmaFirst studyNCT05110976 · 170 enrolled · United States, Germany, United Kingdom
- Jul 15, 2024Phase 2 study in AsthmaNCT06529419 · 537 enrolled · United States, Argentina, Belgium and more
- Jul 29, 2024Phase 1 study in AsthmaNCT06531811 · 32 enrolled · United States
- Jan 22, 2025Phase 1 study in AsthmaNCT06795906 · 24 enrolled · Germany
- Jun 11, 2025Phase 1 study in AsthmaNCT07065331 · 10 enrolled · United States
- Jul 10, 2025Named sunakimentINNProposed as its International Nonproprietary Name in WHO's List 133 · before, AZD8630
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07065331Asthma · United States | 1 | Completed | Sep 19, 2025 | 10 |
| NCT06795906Asthma · Germany | 1 | Completed | Jun 27, 2025 | 24 |
| NCT06531811Asthma · United States | 1 | Completed | Oct 3, 2024 | 32 |
| NCT06529419Asthma · United States, Argentina, Belgium and more | 2 | Completed | Feb 4, 2026 | 537 |
| NCT05110976Asthma · United States, Germany, United Kingdom | 1 | Completed | Aug 2, 2023 | 170 |
How it is read
Names in the registry
- “AZD8630”, 4 entries
- “AZD8630 (test formulation) via test inhaler”, 1 entry
- “AZD8630 (reference formulation) via Monodose inhaler”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.